ASTRAZEN Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > astrazen

Technical Analysis

Technical Strength: 6.7 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 62.4. According to RSI analysis, astrazen is technically strong. 9.0 ASTRAZEN RSI Chart
MACD (?) MACD: 93.0 and Signal Line: 106.0. According to MACD analysis, astrazen is marginally weak. 3.0 ASTRAZEN MACD Chart
Simple Moving Average (?) According to simple moving average analysis, astrazen is in a strong uptrend. Major support levels are 2541.818, 2280.701, 2035.35. 10.0 ASTRAZEN Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, astrazen is in a strong uptrend. Major support levels are 2510.984, 2332.459, 2027.035. 10.0 ASTRAZEN Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.672. 5.0 ASTRAZEN Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 2546.566 and 2465.5. Resistance level is 2809.0. 6.5 ASTRAZEN Fibonacci Retracement Chart
Average True Range (?) ATR: 119 NA ASTRAZEN Average True Range Chart
Average Directional Index (?) ADX is 45.8 which means ASTRAZEN is in a trend. NA ASTRAZEN Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
November 15, 2019
Open Price 2647.7
High Price 2689.0
Low Price 2600.0
Close Price 2622.85
Absolute Change -25.95
Percentage Change -0.98%
Weekly Change 5.12%
Monthly Change 19.3%
Yearly Change 56.3%
52-week high 2809.0
52-week low 1306.05
Corporate Actions
ExDate Purpose
August 20, 2019 INT DIV-RE 1 PER SH
August 30, 2018 ANNUAL GENERAL MEETING
September 04, 2017 Annual General Meeting
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.515
Confidence in Beta1.5%
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 15 November 2019: Deliverable Quantity:8.31e+04 NA ASTRAZEN Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 15 November 2019: Daily Volatility:0.4891 NA ASTRAZEN Annualized Daily Volatility (Spot Price) Chart

Announcements

December 19, 2018 Reply to Clarification Sought ASTRAZEN: The Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 07-Dec-2018, regarding " AstraZeneca Pharma India Limited has informed the Exchange regarding 'We wish to inform that the Company and Abbott have today entered into a Distribution Agreement for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is Company??s leading diabetes medicine. Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET. The Company will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo. '.". On basis of above the Company is required to clarify following: 1. Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;
April 18, 2018 AsPress ReleasestraZeneca Pharma India Limited has informed the Exchange regarding a press release dated April 17, 2018, titled "News Release dated 17th April 2018".
See all Announcements

Board Meetings

Date Meeting Date Purpose
October 25, 2019 November 11, 2019 Financial Results To consider and approve the financial results for the period ended September 30, 2019
July 30, 2019 August 07, 2019 Financial Results/Dividend To consider and approve the financial results for the period ended Jun 30, 2019 and dividend
See all Board Meetings

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play